

# Inflammation and Cancer

## ***Inflammation and Cancer: An Ancient Link with Modern Evidence***

***S. Perwez Hussain, Ph.D.  
Head, Pancreatic Cancer Unit  
Lab of Human Carcinogenesis  
CCR, NCI, NIH***

# Inflammation and Cancer

## INFLAMMATION AND CANCER

---


**PubMed Search Oct 11, 2016  
Inflammation & cancer= 37,201 articles  
published in the last 10 years**

**In 1863 Rudolf Virchow noted leucocytes in neoplastic tissues and made a connection between inflammation and cancer.**

**Recent Evidence have supported Virchow's hypothesis, and the links between inflammation and cancer may have potential implications in prevention and treatment.**

# Aspirin Use

## Aspirin Use Reduced Risk of Cancer Deaths



# Chronic Inflammation and Infection

## CHRONIC INFLAMMATION AND INFECTION CAN INCREASE CANCER RISK

### Inherited

Disease	Tumor Site	Risk
Hemochromatosis	Liver	219
Hereditary Pancreatitis	Pancreas	53
Ulcerative Colitis	Colon	6
Crohn's Disease	Colon	3

“18% of human cancers, i.e., 1.6 million per year, are related to infection.”

### Acquired

#### Viral

Disease	Tumor Site	Risk
Hepatitis B	Liver	88
Hepatitis C	Liver	30

#### Bacterial

Disease	Tumor Site	Risk
Helicobacter Pylori	Gastric	11
PID	Ovary	3


#### Parasitic

Disease	Tumor Site	Risk
S. hematobium	Urinary Bladder	2-14
S. japonicum	Colon	2-6
Liver Fluke	Liver	14

#### Chemical/ Physical/Metabolic


Disease	Tumor Site	Risk
Acid reflux	Esophagus	50-100
Pancreatitis	Pancreas	17
Asbestos	Lung pleural	>10
Obesity	Multiple sites	1.3-6.5

# Stress and Inflammation




# Free Radicals and Inflammation

## FREE RADICALS AND INFLAMMATION




# Tumorigenesis

## Inflammation Contributes to Various Stages of Tumorigenesis




# Inflammation Types

## Types of Inflammation in Tumorigenesis and Cancer




# Obesity, Metabolic Syndrome and Cancer

## Obesity, Metabolic Syndrome and Cancer




# Macrophage and Adipocyte Functions

## CONVERGENCE OF MACROPHAGE AND ADIPOCYTE FUNCTIONS IN OBESITY AND METABOLIC SYNDROME




# Chronic Inflammation

## CHRONIC INFLAMMATION AFFECTS MULTIPLE PATHWAYS



# Nitric Oxide Synthase


## NITRIC OXIDE SYNTHASE



# NOS2 Induction


## INDUCTION OF NOS2

---



# p53 Transrepresses NOS2

## p53 TRANSREPRESSES NOS2: EXAMPLE OF p53 NEGATIVE FEEDBACK LOOP



# Ulcerative Colitis Colon

## ULCERATIVE COLITIS COLON

---

**Normal**



**UC Lesions**



**Ulceration**


**UC Cancer**



**Cancer**


# Colorectal Cancer and Ulcerative Colitis

## CUMULATIVE RISK OF DEVELOPING COLORECTAL CANCER FOR A PATIENT WITH ULCERATIVE COLITIS




# NOS2 Expression

**NOS2 EXPRESSION CORRELATES WITH p53 SER15 PHOSPHORYLATION AND EXPRESSION OF p21 and MDM2 IN ULCERATIVE COLITIS**



# Nitric Oxide


## NITRIC OXIDE CAN ACTIVATE THE PROTECTIVE p53 STRESS RESPONSE PATHWAY



# Hypothesis

**HYPOTHESIS: NITRIC OXIDE AND OXYRADICALS ASSOCIATE WITH CANCER-RELATED MUTATIONS IN CHRONIC INFLAMMATORY DISEASES PRIOR TO CANCER**

---



# p53 Mutation

## INCREASED TISSUE p53 MUTATION LOAD IN CHRONIC INFLAMMATORY AND OXYOVERLOAD CONDITIONS

---


- Ulcerative Colitis
- Hemochromatosis
- Wilson Disease
- Lungs from Tobacco Smokers
- Chronic Pancreatitis ?

---

Hussain et al., Cancer Res. 60: 333, 2000  
Hussain et al., Proc. Natl. Acad. Sci. 97: 12770, 2000  
Hussain et al., Cancer Res. 61: 6350, 2001  
Hagiwara et al., Cancer Res., 66:8309, 2006

# Stress Response Pathway


**NITRIC OXIDE CAN ACTIVATE THE PROTECTIVE p53 STRESS RESPONSE PATHWAY AND INDUCE ONCOGENIC p53 MUTATIONS**



# Inflammation and Pancreatic Cancer


## Inflammation and Pancreatic Cancer

---





# Chronic Pancreatitis

## Increased Risk of Pancreatic Cancer in Patients with Chronic Pancreatitis



# Components of Pancreatic Cancer


## COMPONENTS OF PANCREATIC CANCER



H/E


# Inflammatory Changes

## INFLAMMATORY CHANGES DURING DEVELOPMENT AND PROGRESSION OF PANCREATIC CANCER



# Oncogenic KRAS

Inflammation enhances and maintains a pathologic level of oncogenic KRAS in pancreatic cancer




Daniluk et. al.,  
JCI, 2012

# NOS2 expression



Increased NOS2 expression is associated with poor survival of resected pancreatic cancer patients (Stage I/II).

## Human Pancreatic Ductal Adenocarcinoma

K/M Survival Curve



NOS2 (IHC)



# Pancreatic cancer mouse model

## Genetically Engineered Mouse Model of Pancreatic Cancer


---

\*LSL-Kras-G12D X p53 LSL R172H X Pdx-Cre 1 (KPC)

**Pancreatic Ductal Adenocarcinoma (PDAC)**  
(Median Survival = 4-5 months)



(PDAC)




H/E

# NOS2 knockout mouse

**HYPOTHESIS: NO<sup>•</sup> Enhances Pancreatic Cancer Progression**

- NOS2-deficiency Enhances Survival in KPC Mice




NOS2 deletion in genetically engineered mouse model of pancreatic cancer

# Nitric oxide and pancreatic cancer

## NO<sup>•</sup> and Pancreatic Cancer


---



FOXO: Fork-head box transcription factor (subclass O)

# Nostrin


## NOSTRIN is a Negative Regulator of Disease Aggressiveness



# MIF

## Macrophage Migration Inhibitory Factor (MIF)

---



# MIF, Inflammation, and Cancer

## MIF, Inflammation and Cancer

Immunity, 26, 2007

### Perspective



## Macrophage Migration Inhibitory Factor: A Probable Link between Inflammation and Cancer

Richard Bucala<sup>1,\*</sup> and Seamas C. Donnelly<sup>2,\*</sup>

The pleiotropic effects of macrophage migration inhibitory factor (MIF) place it in a central position in the immunopathogenesis of many diseases. Here we discuss the current understanding of MIF's role and highlight it as a potential link between inflammatory activation and malignant progression.

J. Exp. Med., 190, 1999

## At the Crossroads of Inflammation and Tumorigenesis



By Carlos Cordon-Cardo<sup>\*</sup> and Carol Prives<sup>‡</sup>

---

From the <sup>\*</sup>Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021; and the <sup>‡</sup>Department of Biological Sciences, Columbia University, New York, New York 10027


# MIF expression

Increased expression of MIF in tumors from pancreatic ductal adenocarcinoma cases



# Higher MIF Expression and PDAC


A Higher MIF Expression is Associated with Poorer Survival in Resected PDAC Cases



# MIF expression



A higher expression of MIF is associated with poor survival in human PDAC

## Validation in Independent Cohorts






# MIF Overexpression

## MIF-Overexpression Enhanced Tumor Growth and Metastasis in Orthotopic Mouse Model



# MIF and EMT-related genes

## MIF Induces a Marked Change in Global Gene Expression Profile including EMT-related Genes in Orthotopic Tumors



- MIF over-expressing tumors are poorly differentiated.

- MIF induces a change in global gene expression profile.

- MIF over-expressing tumors showed expression of EMT-related genes.

# MIF and liver metastasis

## Exosomal MIF Enhances Liver Metastasis in PDAC

ARTICLES

nature  
cell biology


### Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver

Bruno Costa-Silva<sup>1</sup>, Nicole M. Aiello<sup>2</sup>, Allyson J. Ocean<sup>3</sup>, Swarnima Singh<sup>1</sup>, Haiying Zhang<sup>1</sup>, Basant Kumar Thakur<sup>1,4</sup>, Annette Becker<sup>1</sup>, Ayuko Hoshino<sup>1</sup>, Milica Tešić Mark<sup>5</sup>, Henrik Molina<sup>5</sup>, Jenny Xiang<sup>6</sup>, Tuo Zhang<sup>6</sup>, Till-Martin Theilen<sup>1</sup>, Guillermo García-Santos<sup>1</sup>, Caitlin Williams<sup>1</sup>, Yonathan Ararso<sup>1</sup>, Yujie Huang<sup>1</sup>, Gonçalo Rodrigues<sup>1,7</sup>, Tang-Long Shen<sup>8</sup>, Knut Jørgen Labori<sup>9</sup>, Inger Marie Bowitz Lothe<sup>10,11</sup>, Elin H. Kure<sup>11</sup>, Jonathan Hernandez<sup>12</sup>, Alexandre Doussot<sup>12</sup>, Saya H. Ebbesen<sup>1</sup>, Paul M. Grandgenett<sup>13</sup>, Michael A. Hollingsworth<sup>13</sup>, Maneesh Jain<sup>14</sup>, Kavita Mallya<sup>14</sup>, Surinder K. Batra<sup>14</sup>, William R. Jarnagin<sup>12</sup>, Robert E. Schwartz<sup>15</sup>, Irina Matei<sup>1</sup>, Héctor Peinado<sup>1,16</sup>, Ben Z. Stanger<sup>2,19</sup>, Jacqueline Bromberg<sup>17,19</sup> and David Lyden<sup>1,18,19</sup>

Pancreatic ductal adenocarcinomas (PDACs) are highly metastatic with poor prognosis, mainly due to delayed detection. We hypothesized that intercellular communication is critical for metastatic progression. Here, we show that PDAC-derived exosomes induce liver pre-metastatic niche formation in naive mice and consequently increase liver metastatic burden. Uptake of PDAC-derived exosomes by Kupffer cells caused transforming growth factor  $\beta$  secretion and upregulation of fibronectin production by hepatic stellate cells. This fibrotic microenvironment enhanced recruitment of bone marrow-derived macrophages. We found that macrophage migration inhibitory factor (MIF) was highly expressed in PDAC-derived exosomes, and its blockade prevented liver pre-metastatic niche formation and metastasis. Compared with patients whose pancreatic tumours did not progress, MIF was markedly higher in exosomes from stage I PDAC patients who later developed liver metastasis. **These findings suggest that exosomal MIF primes the liver for metastasis and may be a prognostic marker for the development of PDAC liver metastasis.**


# MIF and pancreatic cancer

## MIF-induced disease aggressiveness in pancreatic cancer



# miR-301b and pancreatic cancer



## MIF/miR-301b/NR3C2 Axis in Pancreatic Cancer



# MIF deficiency

## MIF-deficiency enhanced survival and reduced metastasis in KPC mice


### KPC Mouse Model



MKPC= MIF-deficient KPC mice

# miRNA and Cancer

# miRNA and Cancer




miR	N	Tumor type
miR-21	6	Breast, colon, lung, pancreas, prostate, stomach
miR-17-5p	5	Breast, colon, lung, pancreas, prostate
miR-191	5	Colon, lung, pancreas, prostate, stomach
miR-29b-2	4	Breast, colon, pancreas, prostate
miR-223	4	Colon, pancreas, prostate, stomach
miR-128b	3	Colon, lung, pancreas
miR-199a-1	3	Lung, pancreas, prostate
miR-24-1	3	Colon, pancreas, stomach
miR-24-2	3	Colon, pancreas, stomach
miR-146	3	Breast, pancreas, prostate
miR-155	3	Breast, colon, lung
miR-181b-1	3	Breast, pancreas, prostate
miR-20a	3	Colon, pancreas, prostate
miR-107	3	Colon, pancreas, stomach
miR-32	3	Colon, pancreas, prostate
miR-92-2	3	Pancreas, prostate, stomach
miR-214	3	Pancreas, prostate, stomach
miR-30c	3	Colon, pancreas, prostate
miR-25	3	Pancreas, prostate, stomach
miR-221	3	Colon, pancreas, stomach
miR-106a	3	Colon, pancreas, prostate

The list includes 21 commonly up-regulated microRNAs in 3 or more (N) types of solid cancers ( $P$  value =  $2.5 \times 10^{-3}$ ).

# Inflammation, miRNA, and Cancer

## INFLAMMATION, microRNA AND CANCER



# Chronic Inflammatory Diseases

## Alterations in miRNA Expression in Cancer-Prone Chronic Inflammatory Diseases

---

**Ulcerative  
Colitis**



miR-21, miR-192, miR-375,  
miR-126, miR-195, miR-23a

**Chronic  
Pancreatitis**




miR-100, miR-10b, miR-125,  
miR-199, miR-99

---

# Balance of Inflammatory Signals

Overall Balance of Inflammatory Signals Determine the Outcome



# Summary

## Summary

- Many chronic inflammatory diseases increase cancer risk.
- Inflammatory and immune mediators contribute to different stages of tumor development and progression.
- NO can activate p53 stress response pathway and may also induce oncogenic p53 mutation in ulcerative colitis.
- Increased Expression of inflammatory mediators (e.g., MIF and NO) enhances disease aggressiveness in pancreatic cancer.
- Targeting MIF and NO-induced signaling pathways increased survival in mouse model with lethal pancreatic cancer.
- The highly complex interactions of immune and inflammatory signaling determines the overall effect of inflammation on tumorigenesis.